Surrey Heartlands

Joint Formulary & PAD

Relugolix - Prostate cancer

You are here : Home > Formulary Search > Relugolix - Prostate cancer

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :
Important

Specialist to prescribe at least 1 month treatment, prior to transfer of care

Documentation

NICE Technology Appraisal
Relugolix for treating hormone-sensitive prostate cancer NICE TA995
Evidence Review
Relugolix for prostate Cancer - TA995 NICE briefing paper - October 2024
Information
Relugolix in Prostate Canver -Prescribing Support Fact sheet - May 2025.pdf

PAD Profile

ChemicalSubstance :
Relugolix
Indication :
Prostate cancer
Group Name :
Keywords :
Brand Names Include :
Orgovyx
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Relugolix is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Prostate cancer.

Committee Recommendations (2)

07 May 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status for relugolix in the treatment of Prostate Cancer.

A BLUE (with specialist initiation) traffic light status was agreed, with at least 1 month prescribing of relugolix by the specialist team prior to transfer of care.

05 Feb 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves relugolix for treating hormone-sensitive prostate cancer in line with NICE TA995).

Relugolix for this indication will be considered as RED on the traffic light system.

Prescribing should be initiated and continued by a specialist clinician. If the patient has already been initiated on this medicine by a specialist clinician, please ensure this is recorded as a ‘Hospital Only Drug’ in the patient’s medication list, in order to be alert to potential side-effects and interactions with other medicines prescribed in primary care.